COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ICCVAM Logo

ICCVAM Biennial Report 2018-2019

ICCVAM Biennial Report 2018-2019
Menu
https://ntp.niehs.nih.gov/go/892369

Key NICEATM and ICCVAM Accomplishments and Impact

Key accomplishments of ICCVAM and ICCVAM member agencies in support of the ICCVAM mission during 2018 and 2019 include:

  • Publication of ICCVAM Strategic Roadmap. This document, developed with participation from the 16 ICCVAM member agencies, describes a framework for safety testing that will provide more human-relevant toxicology data while reducing the use of animals. To facilitate access to the roadmap by ICCVAM’s international partners, the roadmap was translated into five languages.
  • Development of the Collaborative Acute Toxicity Modeling Suite. The ICCVAM Acute Toxicity Workgroup organized a global project to develop in silico models of acute oral systemic toxicity that predict five specific endpoints needed by regulatory agencies. This project produced the Collaborative Acute Toxicity Modeling Suite, an online resource for screening organic chemicals for acute oral toxicity.
  • Expansion of NICEATM’s Integrated Chemical Environment. NICEATM created the Integrated Chemical Environment to provide curated data and tools for safety assessment of chemicals. Updates of the Integrated Chemical Environment during 2018 and 2019 allowed users to run in vitro to in vivo extrapolation analyses, access quantitative structure-activity relationship predictions of endocrine activity and chemical properties, and explore data on mixtures.
  • DoD strategic roadmap to promote the use of new approach methodologies in rapid chemical assessment. Currently in development, this DoD-specific roadmap will help laboratories across DoD to better define their chemical assessment needs and collaborate on development or refinement of appropriate non-animal approaches for testing.
  • EPA draft policy on non-animal methods for skin sensitization. In 2018, EPA announced a draft science policy to reduce animal use in testing strategies that evaluate chemicals for their ability to cause an allergic reaction, inflammation, or sensitization of the skin. The draft policy was the result of national and international collaboration.
  • EPA initiatives to reduce animal use. In 2019, EPA announced a directive to prioritize efforts to reduce animal testing, which called for reducing mammal study requests and funding 30% by 2025 and completely eliminating them by 2035. EPA has also established criteria for waiving some types of animal study requirements.
  • EPA strategic plan for the Toxic Substances Control Act. In 2018, EPA released a plan for that describes how the agency will promote development and implementation of methods and strategies that reduce, refine, or replace vertebrate animal testing to provide chemical safety information required under the Toxic Substances Control Act.
  • FDA predictive toxicity roadmap implementation. In 2017, FDA published its Predictive Toxicology Roadmap for integrating predictive toxicology methods into safety and risk assessments. FDA held meetings in 2018 and 2019 to solicit comments on the roadmap and highlight work done to support and implement it.
Cover of ICCVAM Strategic Roadmap Document (Jan 2018)

U.S. Strategic Roadmap

The U.S. Strategic Roadmap was developed with participation from all ICCVAM member agencies and multiple interagency workgroups, with input from a broad range of stakeholder groups.
Tags: